Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails

Background: Immune checkpoint inhibition therapy with monoclonal antibody against programmed cell death protein 1 (PD-1), including nivolumab and pembrolizumab, has demonstrated powerful clinical efficacy in the treatment of advanced cancers. However, there is no evidence-based systematic review on...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hui, Fu, Xiaoyan, Li, Qian, Niu, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504777/
https://www.ncbi.nlm.nih.gov/pubmed/31118893
http://dx.doi.org/10.3389/fphar.2019.00387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504777/
https://www.ncbi.nlm.nih.gov/pubmed/31118893
http://dx.doi.org/10.3389/fphar.2019.00387

Ejemplares similares